Outpatient Facility Coding Alert - 2004 Issue 3
Drug Coding: CMS Throws Practices a Curve Ball With J0880 Reversal
Subscribe or sign in to view the full article.
Article Overview
This article covers a CMS update that changed how certain injectable anemia drugs are reported under Medicare, especially for Aranesp in ESRD and non-ESRD settings. It is relevant to physician offices, oncology and nephrology practices, and coders who need to understand the general scope of the CMS guidance, payer coverage considerations, and documentation items mentioned in the discussion.
Why This Topic Matters
The article matters because a late CMS change affected which injectable drug codes remain payable in different care settings, creating billing uncertainty for practices that report anemia therapies. It also highlights the need to confirm payer-specific requirements and documentation expectations before submitting claims.
What You Will Learn
- How a CMS reversal affected billing options for a drug code used in anemia treatment
- How the article distinguishes ESRD and non-ESRD reporting scenarios
- What kinds of payer and documentation issues practices were advised to verify
- Why different practice settings may prefer one reporting option over another
Who Should Read This
- Medical coders
- Billing staff
- Oncology practices
- Nephrology practices
- Physician office staff
- Revenue cycle professionals
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com